Epilepsy 2017 Global Market Growth, Opportunities and Analysis, Forecast To 2022

Market Analysis Research Report on “Global Epilepsy Market 2017 Industry Growth, Size, Trends, Share, Opportunities and Forecast to 2022” to their research database

Global Epilepsy Market

“Epilepsy – Market Insights, Epidemiology and Market Forecast-2025” report provides an overview of the Epilepsy, epidemiology and market trend of the Epilepsy for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Epilepsy from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Epilepsy till 2025.The Report also covers market drivers, market barriers and unmet medical need.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2387526-epilepsy-market-insights-epidemiology-and-market-forecast-2025

Our report provides the subtype specific prevalent population i.e. Focal Epilepsy, Generalized Epilepsy and Unclassified Epilepsy. In addition, the report also covers the prevalent cases of TSC associated Epilepsy in 6MM (excluding Japan). According to DelveInsight, the prevalent population of Epilepsy is expected to reach up to XXX cases by the end of 2025 at a CAGR of 4.13% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

The market is dominated by approved therapies that are used for the treatment of
Epilepsy. The three best selling drugs of 2016 were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB).

United States contributes the major share of Epilepsy market as compared to EU5 countries and Japan. The therapeutic market of Epilepsy in 7MM is expected to reach USD 8.8 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:
• The report will help in developing business strategies by understanding the trends shaping and driving the Epilepsy market in 7MM.
• Organize sales and marketing efforts by identifying the best opportunities for Epilepsy in US, European Union 5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
• To understand the future competition in the Epilepsy market (7MM) and Insightful review of the key market drivers and barriers.
• The report provides historical as well as forecasted epidemiology of Epilepsy in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
• The Report also covers the detailed historical and forecasted Epilepsy market covering United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom), Japan and Rest of the World (RoW) from 2015-2025.

Report Summary
2. Epilepsy Disease Background
2.1. Introduction
2.2. Causes
2.3. Symptoms
2.4. Classification
2.5. Risk factors
2.6. Diagnosis
2.7. TSC Mutations in Epilepsy
2.8. Current Treatment & Medical Practices
3. Epidemiology and Patient Population
3.1. Key Points:
4. United States
4.1. Prevalence of Epilepsy in United States
4.2. Gender specific prevalence in United States
4.3. Sub-type specific prevalence in United States
4.4. Prevalence of TSC associated Epilepsy in the United States
5. Germany
5.1. Prevalence of Epilepsy in Germany
5.2. Gender specific prevalence in Germany
5.3. Sub-type specific prevalence in Germany
5.4. Prevalence of TSC associated Epilepsy in the Germany
6. France
6.1. Prevalence of Epilepsy in France
6.2. Gender specific prevalence in France
6.3. Sub-type specific prevalence in France
6.4. Prevalence of TSC associated Epilepsy in the France
7. Italy
7.1. Prevalence of Epilepsy in Italy
7.2. Gender specific prevalence in Italy
7.3. Sub-type specific prevalence in Italy
7.4. Prevalence of TSC associated Epilepsy in the Italy
8. Spain
8.1. Prevalence of Epilepsy in Spain
8.2. Gender specific prevalence in Spain
8.3. Sub-type specific prevalence in Spain
8.4. Prevalence of TSC associated Epilepsy in the Spain
9. United Kingdom
9.1. Prevalence of Epilepsy in United Kingdom
9.2. Gender specific prevalence in United Kingdom
9.3. Sub-type specific prevalence in United Kingdom
9.4. Prevalence of TSC associated Epilepsy in the UK
10. Japan
10.1. Prevalence of Epilepsy in Japan
10.2. Gender specific prevalence in Japan
10.3. Sub-type specific prevalence in Japan
11. Treatment Algorithm
11.1. NICE Guidelines
11.2. Treatment options in the management of Epilepsy in patients with TSC
11.3. Epilepsy treatment in TSC: Clinical Recommendations
12. Unmet Needs
13. Competitive Landscape-Marketed Drugs
13.1. Vimpat: UCB
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Vimpat Sales
13.2. Lyrica: Pfizer
13.2.1. Drug Description
13.2.2. Product Profile
13.2.3. Lyrica Sales
13.3. Banzel: Eisai
13.3.1. Drug Description
13.3.2. Product Profile
13.3.3. Banzel Sales
13.4. Briviact: UCB Pharma
13.4.1. Drug Description
13.4.2. Product Profile
13.4.3. Briviact Sales
13.5. Keppra: UCB
13.5.1. Drug Description
13.5.2. Product Profile
13.5.3. Keppra Sales
13.6. Keppra XR (levetiracetam XR): UCB
13.6.1. Drug Description
13.6.2. Product Profile
13.6.3. Keppra Sales
13.7. Topamax: Janssen
13.7.1. Drug Production
13.7.2. Product Profile
13.7.3. Topamax Sales
13.8. Lamictal: GlaxoSmithKline
13.8.1. Drug Description
13.8.2. Product Profile
13.8.3. Lamictal Sales
13.9. Neurontin: Pfizer
13.9.1. Drug Description
13.9.2. Product Profile
13.9.3. Neurontin Sales
13.10. Zonegran: Eisai
13.10.1. Drug Description
13.10.2. Product Profile
13.10.3. Zonegran Sales
13.11. Trileptal: Novartis
13.11.1. Drug Description
13.11.2. Product Profile
13.11.3. Trileptal Sales
13.12. Zebinix (Aptiom): Dainippon Sumitomo Pharma/Eisai
13.12.1. Drug Description
13.12.2. Product Profile
13.12.3. Zebinix (Aptiom) Sales
13.13. Fycompa: Eisai
13.13.1. Drug Description
13.13.2. Product Profile
13.13.3. Fycompa Sales

Buy Now@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2387526

Contact Info:
Name: Norah Trent
Email: Send Email
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1 646 845 9349 (US)/+44 208 133 9349(UK)
Website: http://www.wiseguyreports.com

Release ID: 251711